CKD progression — RAAS inhibition and SGLT2 nephroprotection
nephroprotection · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Evidence-based strategy to slow CKD progression using maximally tolerated ACE inhibitor/ARB plus an SGLT2 inhibitor in proteinuric or diabetic CKD, with BP, glycaemic and lifestyle optimisation. SGLT2 inhibitors reduce progression and cardiovascular events across diabetic and non-diabetic CKD.
Red flags
- Creatinine rise >30% or hyperkalaemia >6.0 mmol/L after RAAS blockade
- Rapidly declining eGFR (>5 mL/min/year) despite therapy
- Euglycaemic DKA on SGLT2 inhibitor
- New heavy proteinuria or active urinary sediment (glomerulonephritis)
- Features of renovascular disease (flash pulmonary oedema, bilateral stenosis)
Assessment
Differential diagnosis
- Diabetic kidney disease
- Hypertensive nephrosclerosis
- Chronic glomerulonephritis (IgA, FSGS)
- Reflux/obstructive nephropathy
- Polycystic kidney disease (not SGLT2-driven)
- Superimposed AKI accelerating decline
Investigations
- eGFR trend and urine ACR (albumin:creatinine ratio)
- U&E, potassium and bicarbonate
- HbA1c and lipid profile
- Blood pressure (home/ambulatory)
- Urinalysis for haematuria/active sediment
- Renal ultrasound if obstruction or structural cause suspected
Management
- Confirm CKD, quantify albuminuria with ACR and establish eGFR slope over time
- Identify and treat reversible accelerants (uncontrolled BP, nephrotoxins/NSAIDs, obstruction, poor glycaemic control)
- Start and uptitrate an ACE inhibitor or ARB to the maximum tolerated dose in CKD with ACR >=3 mg/mmol or hypertension
- Check U&E 1-2 weeks after starting/uptitrating RAAS blockade; tolerate up to 25-30% creatinine rise and potassium up to 5.5 mmol/L
- Add an SGLT2 inhibitor (dapagliflozin/empagliflozin) in CKD with ACR >=22 mg/mmol or diabetic kidney disease, down to eGFR ~20 mL/min/1.73m2
- Counsel about an expected small initial eGFR dip (<10%) after SGLT2 start that then stabilises — do not stop for this
- Give sick-day guidance to pause SGLT2 inhibitor during acute illness/dehydration (ketoacidosis risk)
- Optimise blood pressure to target <130/80 (individualised) using the lowest effective additional agents
- In residual albuminuria/diabetic CKD consider adding finerenone where potassium and eGFR permit
- Reinforce lifestyle: smoking cessation, sodium <2 g/day, weight management, exercise
- Monitor eGFR, ACR and potassium at 3-6 monthly intervals
- Refer to nephrology for rapidly declining eGFR, ACR >=70 mg/mmol, or diagnostic uncertainty
Drugs & doses
Ramipril 2.5-10 mg PO daily (titrate to max tolerated)
Losartan 50-100 mg PO daily OR candesartan 8-32 mg PO daily
Dapagliflozin 10 mg PO once daily
Empagliflozin 10 mg PO once daily
Finerenone 10-20 mg PO once daily (if eGFR adequate and K+ <=4.8 mmol/L at start)
Atorvastatin 20 mg PO once daily (cardiovascular risk reduction)
Disposition
Primary care/CKD clinic for most; nephrology referral for rapid decline, heavy proteinuria, or uncertain diagnosis. Educate on sick-day medication rules.
Complications & pitfalls
- Hyperkalaemia from RAAS blockade (+/- finerenone)
- Functional AKI if hypovolaemic or on NSAIDs
- Euglycaemic diabetic ketoacidosis (SGLT2)
- Volume depletion/hypotension
- Genital mycotic infections (SGLT2)
- Progression to end-stage kidney disease despite therapy
Exam pearls
- A small stable eGFR dip after RAAS or SGLT2 start is expected and protective — do not stop
- SGLT2 inhibitors now benefit non-diabetic proteinuric CKD too
- Do not combine ACE inhibitor with ARB (harm without benefit)
- Give explicit SGLT2 sick-day rules to prevent euglycaemic DKA
- Hold RAAS blockade during significant intercurrent illness with volume depletion
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.